Basheer Azam, Alsaidi Mohammed, Schultz Lonni, Chedid Mokbel, Abdulhak Muwaffak, Seyfried Donald
Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan, USA.
Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan, USA.
Surg Neurol Int. 2017 May 10;8:75. doi: 10.4103/sni.sni_5_17. eCollection 2017.
Postoperative urinary retention (POUR) is common in neurosurgical patients. The use of alpha-blockade therapy, such as tamsulosin, has benefited many patients with a history of obstructive uropathy by decreasing lower urinary tract symptoms such as distension, infections, and stricture formation, as well as the incidence of POUR. For this study, we targeted patients who had undergone spinal surgery to examine the prophylactic effects of tamsulosin. Increased understanding of this therapy will assist in minimizing the morbidity of spinal surgery.
We enrolled 95 male patients undergoing spine surgery in a double-blind, randomized, placebo-controlled trial. Patients were randomly assigned to receive either preoperative tamsulosin (N = 49) or a placebo (N = 46) and then followed-up prospectively for the development of POUR after removal of an indwelling urinary catheter (IUC). They were also followed-up for the incidence of IUC reinsertions.
The rate of developing POUR was similar in both the groups. Of the 49 patients given tamsulosin, 16 (36%) developed POUR compared to 13 (28%) from the control group ( = 0.455). In the control group, 5 (11%) patients had IUC re-inserted postoperatively, whereas 7 (14%) patients in the tamsulosin group had IUC re-inserted postoperatively ( = 0.616). In patients suffering from axial-type symptoms (i.e., mechanical back pain), 63% who received tamsulosin and 18% from the control group ( = 0.048) developed POUR.
Overall, there was no statistically significant difference in the rates of developing POUR among patients in either group. POUR is caused by a variety of factors, and further studies are needed to shed light on its etiology.
术后尿潴留(POUR)在神经外科患者中很常见。使用α受体阻滞剂治疗,如坦索罗辛,通过减轻下尿路症状,如扩张、感染和狭窄形成,以及POUR的发生率,使许多有梗阻性尿路病病史的患者受益。在本研究中,我们以接受脊柱手术的患者为研究对象,以检验坦索罗辛的预防效果。对这种治疗方法的进一步了解将有助于降低脊柱手术的发病率。
我们在一项双盲、随机、安慰剂对照试验中纳入了95例接受脊柱手术的男性患者。患者被随机分配接受术前坦索罗辛(N = 49)或安慰剂(N = 46),然后在拔除留置尿管(IUC)后对POUR的发生情况进行前瞻性随访。同时对IUC再次插入的发生率进行随访。
两组患者发生POUR的比率相似。在接受坦索罗辛治疗的49例患者中,16例(36%)发生了POUR,而对照组为13例(28%)(P = 0.455)。在对照组中,5例(11%)患者术后IUC再次插入,而坦索罗辛组有7例(14%)患者术后IUC再次插入(P = 0.616)。在患有轴性症状(即机械性背痛)的患者中,接受坦索罗辛治疗的患者中有63%发生了POUR,而对照组为18%(P = 0.048)。
总体而言,两组患者发生POUR的比率在统计学上没有显著差异。POUR由多种因素引起,需要进一步研究以阐明其病因。